Journal of Cutaneous Medicine and Surgery最新文献

{"title":"Acral Melanoma Following Trauma: A Systematic Review and Meta-Analysis.","authors":"Gabrielle J Williams, John F Thompson","doi":"10.1177/12034754261431836","DOIUrl":"https://doi.org/10.1177/12034754261431836","url":null,"abstract":"<p><p>Anecdotal evidence suggests an association between trauma and the subsequent development of acral melanoma. However, good-quality supporting evidence has been lacking, prompting this review which aimed to address the uncertainty by compiling and analyzing the frequency of trauma, tumor features, disease progression, and death due to melanoma for acral site melanomas associated with trauma and cases without a trauma history. A systematic review was performed with searches of Medline, Embase and the Cochrane CENTRAL register of trials to May 15, 2025. Included studies were those that reported cases of acral melanoma and a history or absence of preceding trauma. Data were pooled using a random-effects model. The frequency of trauma with acral site melanomas, tumor features at presentation and death from melanoma were collated and analyzed. From 1448 titles, 97 studies reported cases of acral melanoma with trauma status. Two case-control studies compared the frequency of a trauma history in patients with and without acral melanomas, both reporting that a trauma history was more frequent in patients with acral melanoma (odds ratios 5.2, 95% CI 3.0-8.8 and 8.1, 95% CI 4.3-15.5). Fifty case reports and 45 multicase studies reported acral melanoma features along with trauma history. The extensive evidence analyzed in this review confirmed with considerable confidence that acral melanomas may develop after trauma. The important practical implication of the study findings is that early biopsy of any unusual acral lesion that develops or persists after prior trauma should be considered. This will allow treatment to be undertaken expeditiously if melanoma is diagnosed.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261431836"},"PeriodicalIF":3.9,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine for Skin Involvement in Immunoglobulin A Vasculitis: A Single-Center Case Series and Review of the Literature.","authors":"Maha El Barch, Meryem Safoine, Selma Ouali, Maryam Piram","doi":"10.1177/12034754261433521","DOIUrl":"https://doi.org/10.1177/12034754261433521","url":null,"abstract":"<p><strong>Background: </strong>Immunoglobulin A vasculitis (IgAV) is a systemic small-vessel vasculitis characterized by palpable purpura, often accompanied by joint, gastrointestinal, and/or renal involvement. Although cutaneous manifestations are usually mild and self-limited, they can occasionally present as persistent, severe, or recurrent skin lesions.</p><p><strong>Objectives: </strong>To assess the efficacy and safety of colchicine in the treatment of complicated cutaneous manifestations of IgAV.</p><p><strong>Methods: </strong>We conducted a retrospective chart review of patients treated with colchicine for skin manifestation of IgAV at our vasculitis clinic. This was complemented by a search of the PubMed and MEDLINE databases to identify additional reported cases.</p><p><strong>Results: </strong>A total of 30 cases were included, comprising 13 from our institution and 17 from the literature. Indications for colchicine use were persistent purpura lasting more than 4 weeks (n = 18), severe skin involvement including bullae, ulcerations, or widespread purpura (n = 9), and recurrent lesions after a symptom-free interval of at least 1 month (n = 8). Colchicine led to clinical improvement in 90% of patients (27/30), with complete resolution in 67% (20/30). All 12 patients treated with colchicine monotherapy responded favorably. Doses ranged from 0.6 to 1.8 mg/day, and the time to response varied from a few days to 3 months. No adverse effects were reported.</p><p><strong>Conclusions: </strong>Colchicine appears to be a safe and effective treatment for persistent, severe, or recurrent cutaneous manifestations of IgAV. These findings support its use in clinical practice and highlight the need for prospective controlled studies.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261433521"},"PeriodicalIF":3.9,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Atopic Dermatitis on Growth in Children: A Systematic Review.","authors":"Christopher Shenouda, Grace Xiong, Sana Gupta, Mohannad Abu-Hilal","doi":"10.1177/12034754261442926","DOIUrl":"https://doi.org/10.1177/12034754261442926","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261442926"},"PeriodicalIF":3.9,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Atopic Dermatitis Shared Decision-Making Tool: Implementing the AHEAD Approach in Clinical Practice.","authors":"Andreas Wollenberg, Melinda Gooderham, Norito Katoh, Valeria Aoki, Andrew E Pink, Yousef Binamer, Jonathan I Silverberg","doi":"10.1177/12034754261427403","DOIUrl":"https://doi.org/10.1177/12034754261427403","url":null,"abstract":"<p><strong>Background: </strong>The use of shared decision-making (SDM) in atopic dermatitis (AD) management guidelines is limited.</p><p><strong>Objective: </strong>To develop a tool for implementing the Aiming High in Eczema and Atopic Dermatitis (AHEAD) SDM approach in AD clinical practice.</p><p><strong>Methods: </strong>The international group of 7 expert dermatologists responsible for leading the development of the AHEAD approach initially drafted the tool. A global patient research study and an advisory board that included the leaders of 10 patient advocacy groups captured global patient and nonclinician considerations.</p><p><strong>Results: </strong>The AD SDM tool provides a simple, practical tool for implementing SDM using the AHEAD approach in clinical practice. The tool enables patients to identify and rank their most troublesome AD symptoms, and clinicians to tailor treatment targets to address them. The tool will enable patients to better communicate their disease burden, increase treatment adherence, and improve continuity of care.</p><p><strong>Conclusions: </strong>The AD SDM tool provides a simple, practical tool for implementing SDM using the AHEAD approach. The consolidation of routine outcome measures should streamline the collection and interpretation of clinically relevant patient information. Feedback from patients and clinicians who use the tool will allow for the assessment of its value in clinical practice.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261427403"},"PeriodicalIF":3.9,"publicationDate":"2026-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147673844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality Trends of Non-Malignant Skin Diseases in Canada: A Statistics Canada Analysis, 2000 to 2023.","authors":"Nirav Saini, Ivy Mushamiri, Jason Kreutz, Raed Alhusayen, Fatemeh Jafarian","doi":"10.1177/12034754261431833","DOIUrl":"https://doi.org/10.1177/12034754261431833","url":null,"abstract":"<p><strong>Background: </strong>The epidemiology of non-malignant-as opposed to malignant-skin diseases is frequently overlooked. Contemporary literature suggests there is a high economic burden and risk of health complications of non-malignant skin diseases, which warrants further study. In contrast to the United States, Canada is particularly devoid of research in this area.</p><p><strong>Objective: </strong>This study aimed to explore the national trends in the mortality rates for non-malignant skin diseases (ICD L00-L98) in the Canadian context from 2000 to 2023.</p><p><strong>Methods: </strong>A population-level ecological analysis was conducted using publicly available mortality data from Statistics Canada's Vital Statistics-Death Database. Crude and age-adjusted mortality rates were calculated, and a subsequent Joinpoint regression analysis identified significant inflection points in temporal trends. Annual percent change (APC) was also computed to quantify and delineate fluctuations over time.</p><p><strong>Results: </strong>Across the aggregate of non-malignant skin conditions, there was a net rise in the mortality rates from 2000 (1.00/100 000) to 2023 (2.50/100 000). An inflection point occurred in 2006; the mortality rates shifted from an initial non-significant decline (APC = -3.84%; <i>P</i> = .040) to a sharp rise (APC = 4.09%; <i>P</i> < .001). Mortality rates did not substantially vary by gender.</p><p><strong>Conclusion: </strong>This study examined the trends in mortality rates of non-malignant dermatological mortality trends in the Canadian context, noting an overall increase in mortality rates over time. These findings underscore the significance of mortality attributable to non-neoplastic skin diseases with regard to clinical care and future policy interventions.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261431833"},"PeriodicalIF":3.9,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 25 Year Review of Dermatology Residency Match in Canada.","authors":"Sarah Aly, Ammar Saed Aldien, Sidra Sarfaraz, Ghassan Barnawi, Meghan L McPhie, Chaocheng Liu","doi":"10.1177/12034754261436026","DOIUrl":"https://doi.org/10.1177/12034754261436026","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261436026"},"PeriodicalIF":3.9,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tralokinumab for Chronic Hand Eczema: A 52 Week Observational Case Series.","authors":"Daniel Blaya Imbernón, Malena Finello, Rodrigo Peñuelas Leal, Carolina Labrandero Hoyos, Andrés Grau Echevarría, Elena Pérez Zafrilla, Ángel González García, Alba Nácher Albiach, Laura Giménez Cuenca, Nadia Giner Cerdà, Dolla Logunova, Altea Esteve Martínez, Esther Diez Recio, Violeta Zaragoza Ninet","doi":"10.1177/12034754261431747","DOIUrl":"https://doi.org/10.1177/12034754261431747","url":null,"abstract":"<p><strong>Background: </strong>Chronic hand eczema (CHE) is a multifactorial inflammatory skin disorder with substantial impact on quality of life and work productivity. Systemic treatment options are limited, and published evidence on the use of tralokinumab, an interleukin-13-targeted monoclonal antibody approved for atopic dermatitis, in CHE is limited.</p><p><strong>Objectives: </strong>To evaluate the effectiveness and safety of tralokinumab in adults with moderate-to-severe CHE refractory to topical therapy in an observational setting.</p><p><strong>Methods: </strong>We conducted a retrospective observational study at a tertiary dermatology center. Adults with moderate-to-severe CHE, refractory to high-potency topical corticosteroids and/or calcineurin inhibitors, received subcutaneous tralokinumab (600 mg initial dose, then 300 mg every 2 weeks). Concomitant topical therapy was allowed. Disease severity was assessed using the Hand Eczema Severity Index (HECSI) at baseline and weeks 4, 16, 32, and 52. Responses were assessed achieving HECSI-50, HECSI-75, HECSI-90, and complete clearance (HECSI-100). Data on demographics, disease duration, clinical and etiological subtypes, safety, and response after dose adjustment were collected.</p><p><strong>Results: </strong>Sixteen patients (8 men, 8 women; mean age 56.5 years) were included. Baseline mean HECSI was 120.3. By week 52, 100% achieved HECSI-75, 92.3% HECSI-90, and 53.8% HECSI-100. Dose adjustment to 300 mg every 4 weeks was feasible in 62.5% with maintenance of clinical response. No serious adverse events occurred.</p><p><strong>Conclusions: </strong>Tralokinumab appears associated with clinically meaningful improvement and is well tolerated in severe CHE refractory to topical therapy, including hyperkeratotic and non-atopic forms. Response rates and maintenance after dose adjustment suggest its potential role in CHE management.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261431747"},"PeriodicalIF":3.9,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147622884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isotretinoin-Associated Acute Pancreatitis: An Updated Systematic Review.","authors":"Abdul Aziz Abdul Ghafoor, Hediyeh Vaseli, Mahan Maazi, Arveen Shokravi, Chaocheng Liu, Laurie M Parsons","doi":"10.1177/12034754261436023","DOIUrl":"https://doi.org/10.1177/12034754261436023","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261436023"},"PeriodicalIF":3.9,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoptes Scabiei on Skin Scraping.","authors":"İsmail Hakkı Ünal, Aslan Yürekli","doi":"10.1177/12034754261436000","DOIUrl":"https://doi.org/10.1177/12034754261436000","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261436000"},"PeriodicalIF":3.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147622935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reasons Underlying a \"Sun-Kissed\" Tan: Portraying the Role of Beauty Standards in Shaping Sun Protection.","authors":"Jonathan Lebeau, Sauliha Alli, Agustina Hasbani, François Lagacé, Ivan V Litvinov, Sandra Peláez","doi":"10.1177/12034754261431825","DOIUrl":"https://doi.org/10.1177/12034754261431825","url":null,"abstract":"<p><p><b>Background:</b> In recent decades, the perception of a \"sun-kissed\" tan has often been synonymous with beauty, health, wellness, and wealth. This study examined the relationship between personal beauty perceptions, societal beauty standards, and sun protection behaviors among participants living across Atlantic Canada. <b>Methods:</b> Guided by the theory of planned behavior, participants' (N = 97) attitudes, normative beliefs, and perceived control regarding sun exposure and sun protection behaviors were collected through focus groups discussions. A reflective, iterative coding strategy was developed and discussed by all team members. <b>Results:</b> Participants engaged in combined sun protection behaviors such as using sunscreen and wearing long sleeves, because they were aware of the dangerous effects of ultraviolet radiation. However, occasionally, due to social influences, some participants were prone to engage in purposeful, risky sun exposure to get the desired tan. <b>Discussion:</b> This study contributed to better understanding the \"sunscreen paradox;\" that is, the sun seeking protective behavior that relies on the false belief that applying sunscreen during tanning is enough to prevent the risk of skin cancer. To enhance the adoption of sun protection measures and provide appropriate guidance, health care professionals should be aware of the role personal and social standards of beauty play in shaping sun protection behaviors.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261431825"},"PeriodicalIF":3.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147622861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}